



Study Summary

This study is the first accepted on to the new **ACCORD 2** 'platform'. ACCORD is a UK government sponsored collaborative between multiple parties including regulators, pharma industry, universities and NIHR recognising these times of challenge. The aim is to provide a fast-track route into trials for promising new drugs.

ACelerating COVID-19 dRug Development


The **ACCORD** process identifies new drugs that show potential for treating COVID-19 and starts a Stage 1 trial with a limited number of patients to see if it appears to be effective. This stage lasts about a month once enough patients are involved. If the results show the drug might be useful it moves immediately to Stage 2 where it is tested for a little longer on a larger number of patients. Regulators are kept informed along the way so that if the drug proves successful then it can be quickly approved for general use in treating COVID-19.

BerGenBio

The first drug to go in to trials in this way is **Bemcentinib** which has been used in cancer studies with over 200 patients. This drug inhibits a virus entering a cell and enhances the body's immune response. In the laboratory it appears to work against the coronavirus that causes COVID-19.

Bemcentinib is manufactured by the company **BerGenBio** and the trial is being coordinated by the international clinical trials research company IQVIA.

ACCORD (BerGenBio)



The drug has been shown to be safe and well-tolerated in hundreds of patients and in many cases taken daily for several years. Patients in the trial will take one pill each day in addition to the standard treatment that they are receiving.

News about the ACCORD platform can be found at <https://www.gov.uk/government/news/covid-19-treatments-could-be-fast-tracked-through-new-national-clinical-trial-initiative>



BerGenBio has details about Bemcentinib and this trial at <https://www.bergenbio.com/ceo-letter-covid-19-clinical-trial/>

IQVIA announced their work in ACCORD at <https://www.iqvia.com/locations/united-kingdom/newsroom/2020/04/iqvia-joins-uk-government-collaboration-to-find-covid-19-treatments>



Study Summaries from **TrialsConnect** are not official information for patients or others. They are prepared to aid clinical trials patients in telling their story to family and lay audiences.

www.trialsconnect.org

©2020, TrialsConnect